Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by University of California, San Francisco
Sponsor:
Collaborators:
Celgene Corporation
Genentech
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01542918
First received: February 27, 2012
Last updated: August 13, 2013
Last verified: August 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2017
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)